Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | NANP | Q8TBE9 | 3/20 | 0.38 |
| ▸ | NEU2 | Q9Y3R4 | 5/20 | 0.35 |
| ▸ | NEU1 | Q99519 | 5/20 | 0.32 |
| ▸ | NEU3 | Q9UQ49 | 5/20 | 0.31 |
| ▸ | NEU4 | Q8WWR8 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15806332 | 1.00 | L3MBTL1 (0.53) | L3MBTL1NANPNEU2NEU1NEU3 | |
| SCHEMBL16322512 | 1.00 | L3MBTL1 (0.53) | L3MBTL1NANPNEU2NEU1NEU3 | |
| SCHEMBL16274161 | 1.00 | L3MBTL1 (0.53) | L3MBTL1NANPNEU2NEU1NEU3 | |
| SCHEMBL15473948 | 1.00 | L3MBTL1 (0.53) | L3MBTL1NANPNEU2NEU1NEU3 | |
| SCHEMBL15806331 | 1.00 | L3MBTL1 (0.53) | L3MBTL1NANPNEU2NEU1NEU3 | |
| SCHEMBL27241392 | 1.00 | L3MBTL1 (0.53) | L3MBTL1NANPNEU2NEU1NEU3 | |
| SCHEMBL17936315 | 1.00 | L3MBTL1 (0.53) | L3MBTL1NANPNEU2NEU1NEU3 | |
| SCHEMBL2350516 | 1.00 | L3MBTL1 (0.53) | L3MBTL1NANPNEU2NEU1NEU3 | |
| SCHEMBL15368483 | 0.88 | L3MBTL1 (0.43) | L3MBTL1NANP | |
| SCHEMBL29431811 | 0.88 | L3MBTL1 (0.54) | L3MBTL1NANPNEU2NEU1NEU3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160015729-A1 | GLYCAN-BASED DRUGS, THERAPIES AND BIOMARKERS | B&H BIOTECHNOLOGIES, LLC | 2016-01-21 | — | — | US | disclosed |
| US-9119866-B2 | Glycan-based drugs, therapies and biomarkers | B&H BIOTECHNOLOGIES, LLC | 2015-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015729-A1 | GLYCAN-BASED DRUGS, THERAPIES AND BIOMARKERS | FUT6, UGGT1, CSGALNACT1 | L3MBTL1 1611/4885NANP 94/4885NEU2 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.